CDK4/6抑制剂治疗HR+/HER2?晚期乳腺癌的临床研究进展
Advances in Clinical Research on the CDK4/6 Inhibitors for HR+/HER2? Advanced Breast Cancer
DOI: 10.12677/ACM.2024.143724, PDF,   
作者: 李周娟：青海大学研究生院，青海 西宁；赵久达*：青海大学附属医院乳腺疾病诊疗中心，青海 西宁
关键词: 乳腺癌；细胞周期蛋白依赖性激酶4/6抑制剂；激素受体；疗效；安全性；Breast Cancer； Cell Cycle Protein-Dependent Kinase (CDK) 4/6 Inhibitor； Hormone Receptor； Efficacy； Safety
摘要: 激素受体(HR)阳性，人表皮生长因子受体2 (HER-2)阴性乳腺癌在所有乳腺癌中占比>70%。内分泌治疗是HR+/HER2−乳腺癌的主要治疗方式，但不可避免的会产生耐药。细胞周期蛋白依赖性激酶(CDK) 4/6抑制剂是逆转内分泌治疗耐药的有效药物。这类分子靶向药物为HR+/HER2−乳腺癌患者的临床治疗模式带来变革性的突破。中国已上市的CDK4/6抑制剂包括瑞波西利、哌柏西利、阿贝西利和达尔西利。对于HR+/HER2−晚期乳腺癌，CDK4/6抑制剂联合内分泌治疗已经成为标准方案，能够延长患者的生存。本综述主要阐述四种CDK4/6抑制剂在HR+/HER2−晚期乳腺癌中的疗效、适应症、药物介绍及不良反应的管理，为临床决策提供参考，延长患者生存和提高生活质量。
Abstract: Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER-2)-negative breast cancer accounts for >70% of all breast cancers. Endocrine therapy is the mainstay of treatment for HR+/HER2− breast cancer, but inevitably results in drug resistance. Cell cycle pro-tein-dependent kinase (CDK) 4/6 inhibitors are effective agents for reversing resistance to endo-crine therapy. These molecularly targeted drugs have brought about a transformative break-through in the clinical treatment paradigm for HR+/HER2− breast cancer patients. CDK4/6 inhib-itors that have been marketed in China include Ribociclib, Palbociclib, Abemaciclib and Dalpiciclib. For HR+/HER2− advanced breast cancer, CDK4/6 inhibitors in combination with endocrine therapy have become a standard regimen that can prolong patient survival. This review focuses on the efficacy, indications, safety and drug-drug interactions of four CDK4/6 inhibitors in HR+/HER2− advanced breast cancer, informing clinical decision-making, prolonging patient survival and improving quality of life.
文章引用：李周娟, 赵久达. CDK4/6抑制剂治疗HR+/HER2?晚期乳腺癌的临床研究进展[J]. 临床医学进展, 2024, 14(3): 458-466. https://doi.org/10.12677/ACM.2024.143724

参考文献

[1] Serra, F., Lapidari, P., Quaquarini, E., Tagliaferri, B., Sottotetti, F. and Palumbo, R. (2019) Palbociclib in Metastatic Breast Cancer: Current Evidence and Real-Life Data. Drugs in Context, 8, Article ID: 212579. [Google Scholar] [CrossRef] [PubMed]
[2] Huppert, L.A., Gumusay, O., Idossa, D. and Rugo, H.S. (2023) Systemic Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Stage and Meta-static Breast Cancer. CA: A Cancer Journal for Clinicians, 73, 480-515. [Google Scholar] [CrossRef] [PubMed]
[3] Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., André, F., et al. (2020) 5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5). Annals of Oncology, 31, 1623-1649. [Google Scholar] [CrossRef] [PubMed]
[4] Bevers, T.B., Helvie, M., Bonaccio, E., Calhoun, K.E., Daly, M.B., Farrar, W.B., et al. (2018) Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 16, 1362-1389. [Google Scholar] [CrossRef] [PubMed]
[5] Suski, J.M. (2021) Targeting Cell-Cycle Machinery in Cancer. Cancer Cell, 39, 759-778.
[6] 国家肿瘤质控中心乳腺癌专家委员会, 中国抗癌协会肿瘤药物临床研究专业委员会. CDK4/6抑制剂治疗激素受体阳性人表皮生长因子受体2阴性乳腺癌临床应用专家共识(2023版) [J]. 中华肿瘤杂志, 2023, 45(12): 1003-1017.
[7] Gradishar, W.J., et al. (2021) NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. Journal of the National Comprehensive Cancer Network, 19, 484-493.
https://jnccn.org/view/journals/jnccn/19/5/article-p484.xml
[8] Lei, S., Zheng, R., Zhang, S., Chen, R., Wang, S., Sun, K., et al. (2021) Breast Cancer Incidence and Mortality in Women in China: Temporal Trends and Projections to 2030. Cancer Biology & Medicine, 18, 900-909. [Google Scholar] [CrossRef] [PubMed]
[9] Lu, Y.-S., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Cardoso, F., et al. (2022) Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clinical Cancer Research, 28, 851-859. [Google Scholar] [CrossRef] 
[10] Lu, Y.-S., Mahidin, E.I.B.M., Azim, H., Eralp, Y., Yap, Y.-S., Im, S.-A., et al. (2023) Abstract GS1-10, Primary Results from the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients with Aggressive HR+/HER2− Advanced Breast Cancer Treated with Ribociclib+ Endocrine Therapy vs Physician’s Choice Combination Chemotherapy. Cancer Research, 83, GS1-10-GS1-10. [Google Scholar] [CrossRef] 
[11] Goetz, M.P., Toi, M., Huober, J., Sohn, J., Tredan, O., Park, I.H., et al. (2022) LBA15 MONARCH 3, Interim Overall Survival (OS) Results of Abemaciclib plus a Nonsteroidal Aromatase Inhibitor (NSAI) in Patients (Pts) with HR+, HER2− Advanced Breast Cancer (ABC). Annals of Oncology, 33, S1384. [Google Scholar] [CrossRef] 
[12] Turner, N.C., Slamon, D.J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., et al. (2018) Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. The New England Journal of Medicine, 379, 1926-1936. [Google Scholar] [CrossRef] 
[13] Sledge, G.W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., et al. (2020) The Effect of Abemaciclib plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2, a Randomized Clinical Trial. JAMA Oncology, 6, 116-124. [Google Scholar] [CrossRef] [PubMed]
[14] Xu, B., Zhang, Q., Zhang, P., Hu, X., Li, W., Tong, Z., et al. (2021) Dalpiciclib or Placebo plus Fulvestrant in Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer: A Randomized, Phase 3 Trial. Nature Medicine, 27, 1904-1909. [Google Scholar] [CrossRef] [PubMed]
[15] Slamon, D.J., Neven, P., Chia, S., Fasching, P.A., De, Laurentiis, M., Im, S.-A., et al. (2020) Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. The New England Journal of Medicine, 382, 514-524. [Google Scholar] [CrossRef] 
[16] Im, S.-A., Mukai, H., Park, I.H., Masuda, N., Shimizu, C., Kim, S.-B., et al. (2019) Palbociclib plus Letrozole as First-Line Therapy in Postmenopausal Asian Women with Metastatic Breast Cancer: Results from the Phase III, Randomized PALOMA-2 Study. Journal of Global Oncology, 5, 1-19. [Google Scholar] [CrossRef] 
[17] Finn, R.S., Rugo, H.S., Dieras, V.C., Harbeck, N., Im, S.-A., Gelmon, K.A., et al. () Overall Survival (OS) with First-Line Palbociclib plus Letrozole (PAL + LET) versus Placebo plus Letrozole (PBO + LET) in Women with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer (ER+/HER2− ABC): Analyses from PALOMA-2. Journal of Clinical Oncology, 40, LBA1003.
[18] Johnston, S., Martin, M., Di Leo, A., Im, S.-A., Awada, A., Forrester, T., et al. (2019) MONARCH 3 Final PFS: A Randomized Study of Abemaciclib as Initial Therapy for Advanced Breast Cancer. NPJ Breast Cancer, 5, Article No. 5. [Google Scholar] [CrossRef] [PubMed]
[19] Shao, Z., Liu, Q., Tong, Z., Li, W., Cai, L., Bai, Y., et al. (2022) 21MO Primary Results of a China Bridging, Phase II Randomized Study of Initial Endocrine Therapy (ET) ± Ribociclib (RIB) in Pre- & Postmenopausal Chinese Women with HR+/HER2− ABC. Annals of Oncology, 33, S1438. [Google Scholar] [CrossRef] 
[20] Zhang, Q.Y., Sun, T., Yin, Y.M., Li, H.P., Yan, M., Tong, Z.S., et al. (2020) MONARCH plus: Abemaciclib plus Endocrine Therapy in Women with HR+/HER2− Advanced Breast Cancer: The Multinational Randomized Phase III Study. Therapeutic Advances in Medical Oncology, 12, 1-14. [Google Scholar] [CrossRef] [PubMed]
[21] Slamon, D.J., Neven, P., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S., et al. (2021) Ribociclib plus Fulvestrant for Postmenopausal Women with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the Phase III Randomized MONALEESA-3 Trial: Updated Overall Survival. Annals of Oncology, 32, 1015-1024. [Google Scholar] [CrossRef] [PubMed]
[22] Rugo, H.S., Finn, R.S., Diéras, V., Ettl, J., Lipatov, O., Joy, A.A., et al. (2019) Palbociclib plus Letrozole as First-Line Therapy in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer with Extended Follow-Up. Breast Cancer Research and Treatment, 174, 719-729. [Google Scholar] [CrossRef] [PubMed]
[23] Duan, F., Song, C., Ma, Y., Jiang, K., Xu, F., Bi, X., et al. (2021) Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus. Drug Design, Development and Therapy, 15, 3463-3473. [Google Scholar] [CrossRef] 
[24] Kalinsky, K., Accordino, M.K., Chiuzan, C., Mundi, P.S., Trivedi, M.S., Novik, Y., et al. (2022) A Randomized, Phase II Trial of Fulvestrant or Exemestane with or without Ribociclib after Progression on Anti-Estrogen Therapy plus Cyclin-Dependent Kinase 4/6 Inhibition (CDK 4/6i) in Patients (Pts) with Unresectable or Hormone Receptor-Positive (HR+), HER2-Negative Metastatic Breast Cancer (MBC): MAINTAIN Trial. Journal of Clinical Oncology, 40, LBA1004.
[25] Abstract GS3-06, GS3-06 Palbociclib after CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-Treated ER+/HER2− Metastatic Breast Cancer. Cancer Research, 83, GS3-06. https://aacrjournals.org/cancerres/article/83/5_supplement/gs3-06/717530 [Google Scholar] [CrossRef] 
[26] Hortobagyi, G.N., Stemmer, S.M., Burris, H.A., Yap, Y.S., Sonke, G.S., Paluch-Shimon, S., et al. (2018) Updated Results from MONALEESA-2, a Phase III Trial of First-Line Ribociclib plus Letrozole versus Placebo plus Letrozole in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. Annals of Oncology, 29, 1541-1547. [Google Scholar] [CrossRef] [PubMed]
[27] Sledge, G.W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., et al. (2017) MONARCH 2, Abemaciclib in Combination with Fulvestrant in Women with HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. Journal of Clinical Oncology, 35, 2875-2884. [Google Scholar] [CrossRef] 
[28] Ettl, J. (2019) Management of Adverse Events Due to Cyclin-Dependent Kinase 4/6 Inhibitors. Breast Care, 14, 86-92.
[29] 葛睿, 王碧芸, 江泽飞, 等. 乳腺癌CDK4/6抑制剂相关性不良反应管理共识[J]. 中华肿瘤杂志, 2022, 44(12): 1296-1304.
[30] Rugo, H.S., Huober, J., García-Sáenz, J.A., Masuda, N., Sohn, J.H., Andre, V.A.M., et al. (2021) Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. The Oncologist, 26, E53-E65. [Google Scholar] [CrossRef] [PubMed]
[31] Watson, N.W., Wander, S.A., Shatzel, J.J. and Al‐Samkari, H. (2022) Venous and Arterial Thrombosis Associated with Abemaciclib Therapy for Metastatic Breast Cancer. Cancer, 128, 3224-3232. [Google Scholar] [CrossRef] [PubMed]
[32] Cristofanilli, M., Turner, N.C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., et al. (2016) Fulvestrant plus Palbociclib versus Fulvestrant plus Placebo for Treatment of Hor-mone-Receptor-Positive, HER2-Negative Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy (PALOMA-3): Final Analysis of the Multicentre, Double-Blind, Phase 3 Randomised Controlled Trial. The Lancet Oncology, 17, 425-439. [Google Scholar] [CrossRef] 
[33] Thill, M. and Schmidt, M. (2018) Management of Adverse Events during Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitor-Based Treatment in Breast Cancer. Therapeutic Ad-vances in Medical Oncology, 10, 1-12. [Google Scholar] [CrossRef] [PubMed]

为你推荐